News AI returns voice to paralysed woman after 18 years A stroke survivor has been given back the ability to speak for the first time in 18 years, after a breakthrough
News Biogen trumpets data from ALS trial as FDA decision looms After a torrid couple of years, Biogen can be forgiven for making the most of new data on its tofersen drug for amyotrophic lateral sclerosis (ALS) – with an elevated status among its pipel
News AI-discovered candidates show promise in ALS Candidates slow down motor neurone death in patient samples.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
